Clinical Trials Directory

Trials / Completed

CompletedNCT00516178

Intravenous Fish Oil in Critically Ill Cardiac Patients

Effects of Intravenous n-3 Polyunsaturated Fatty Acid Administration in Critically Ill Cardiac Surgery and Myocardial Infarction Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Centre Hospitalier Universitaire Vaudois · Academic / Other
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Accepted

Summary

A large body of evidence has accumulated showing that n-3 PUFAs exert extensive cardiac effects. The development of commercial solutions of FO opens perspectives for therapeutic applications in patients with acute cardiac conditions.the 3 following hypotheses will be addressed in patients requiring cardiac surgery under cardiopulmonary bypass or after myocardial infarction:perioperative /post-PTCA intravenous fish oil modifies the composition of membrane phospholipids in platelets and cardiac cells, blunts the physiological response to cardiac surgery/myocardial infarction, and reduces the incidence of arrhythmias, and reduces the occurrence of systolic dysfunction.

Detailed description

A. Randomized trial in 40 cardiac surgery patients Early rapid infusion of fish oil (3 times in 24 hours) in cardiac surgery patients. B. Randomized trial 20 myocardial infarction patients (abandonned) Continuous infusion of the same dose over 24hrs in the myocardial infarction patients Additional trial in healthy volunteers (investigating physiological changes after cardiac study): -Open trial in 8 healthy lean volunteers to investigate the impact of the same 0.6 g/kg FO dose IV (Week 1: 3hrs), and then orally on week 2, on platelet n-3 PUFA incorporation, platelet function, heart rate and peak flow response to stress test.

Conditions

Interventions

TypeNameDescription
DRUGFish oil emulsion0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
DRUGSaline3 infusions, perioperative or post-PTCA

Timeline

Start date
2008-01-01
Primary completion
2011-03-01
Completion
2011-04-01
First posted
2007-08-15
Last updated
2016-02-17

Locations

2 sites across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00516178. Inclusion in this directory is not an endorsement.